MedTrace Logo

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

NCT05256797 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 353980

Last updated 2025-03-04

Study results available
· View outcomes & findings →

Summary

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Conditions

Interventions

DRUG

Rivaroxaban

Any rivaroxaban dispensing claim is used as the reference group

DRUG

Apixaban

Any apixaban dispensing claim is used as the exposure group

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Shirley Wang, PhD, ScM · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2022-06-15
Completion
2022-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256797 on ClinicalTrials.gov